Abstract
To overcome unsatisfactory results of classical low-dose cytarabine (LDAC) of cytarabine ≤20 mg twice daily (BID) subcutaneously for 10 days for patients with elderly acute myeloid leukemia (eAML), we evaluated a modified LDAC (mLDAC) of cytarabine 20 mg/m2BID subcutaneously plus etoposide 50 mg BID orally for 14 days. To determine its feasibility, we compared outcomes of 77 and 42 eAML patients who received, respectively, mLDAC and decitabine (DAC; 20 mg/m2intravenously daily for 5 days), which has shown better outcomes compared to those of classical LDAC. Most of baseline characteristics of two groups were well balanced. The mLDAC group had a higher complete response (CR) rate compared to the DAC group (46.8% vs. 19.0%,P< 0.01). Unlike the classical LDAC, mLDAC induced CR in patients with adverse cytogenetics, with its rate similar to that of the DAC group (33.3% vs. 20.0%;P= 0.58). Meanwhile, mucositis, neutropenic fever and invasive aspergillosis were more frequently observed in the mLDAC group, with no difference in early mortality between two groups (P> 0.05). The median overall survival rates of the mLDAC and DAC groups were comparable (8.7 vs 8.3 months, respectively,P= 0.35), presumably because the advantage of higher ...Continue Reading
References
Sep 1, 1975·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G RiveraD W Roberts
Jan 1, 1991·Cancer·F A Greco
Apr 1, 1996·Annals of Hematology·F ThalhammerK Lechner
Aug 7, 2003·Seminars in Radiation Oncology·Andy TrottiPhilip Rubin
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Jul 5, 2005·Blood·Mohamed L SorrorBarry Storer
Jan 26, 2007·The New England Journal of Medicine·Oliver A CornelyDavid Angulo-Gonzalez
Feb 23, 2007·Cancer·Alan K BurnettKeith Wheatley
Jun 21, 2008·Blood·Stefan FaderlHagop M Kantarjian
Nov 15, 2008·Blood·Gunnar JuliussonMartin Höglund
Apr 14, 2010·Blood·David GrimwadeUNKNOWN National Cancer Research Institute Adult Leukaemia Working Group
Feb 19, 2011·Leukemia·P ChevallierJ Delaunay
Mar 26, 2011·Blood·Gunnar Juliusson, UNKNOWN Swedish AML Group
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Gunnar Juliusson
Nov 8, 2011·Haematologica·Michael LübbertHartmut Döhner
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianChristopher Arthur
Sep 12, 2012·Leukemia·A K BurnettUNKNOWN UK National Cancer Research Institute AML Working Group
Mar 30, 2013·Leukemia Research·Xi ZhangLei Gao
Apr 23, 2013·Cancer·Hagop M KantarjianUNKNOWN SPARK-AML1 Investigators
Jul 11, 2013·Blood·Alan K BurnettUNKNOWN UK National Cancer Research Institute AML Working Group
Aug 29, 2013·American Journal of Hematology·Jae-Ho YoonChong-Won Park
Apr 2, 2014·Blood·Jeffrey E LancetEric J Feldman
Jun 14, 2014·Journal of Translational Medicine·Kongfei LiHongyan Tong
Jul 10, 2014·Blood·Hartmut DöhnerJohan Maertens
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
May 20, 2015·Blood·Hervé DombretHartmut Döhner
Aug 20, 2015·Drugs & Aging·Jeffrey C Bryan, Elias J Jabbour
Sep 16, 2015·Leukemia & Lymphoma·Xing-Nong YeHong-Yan Tong
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sergio AmadoriFrédéric Baron
Feb 13, 2016·Leukemia Research·Antonia BainschabArmin Zebisch
Apr 20, 2016·The Oncologist·Maria NietoFrancesco Pignatti